Author:
Hachmann Nicole P.,Miller Jessica,Collier Ai-ris Y.,Ventura John D.,Yu Jingyou,Rowe Marjorie,Bondzie Esther Apraku,Powers Olivia,Surve Nehalee,Hall Kevin,Barouch Dan H.
Abstract
ABSTRACTMultiple lineages of the SARS-CoV-2 Omicron variant (B.1.1.529) have emerged, and BA.1 and BA.2 have demonstrated substantial escape from neutralizing antibodies (NAbs). BA.2.12.1 has now become dominant in the United States, and BA.4 and BA.5 have become dominant in South Africa. Our data show that BA.2.12.1 and BA.4/BA.5 substantially escape NAbs induced by both vaccination and infection. Moreover, BA.4/BA.5 NAb titers, and to lesser extent BA.2.12.1 NAb titers, were lower than BA.1 and BA.2 NAb titers, suggesting that the SARS-CoV-2 Omicron variant has continued to evolve with increasing neutralization escape. These findings have important public health implications and provide immunologic context for the current surges with BA.2.12.1 and BA.4/BA.5 in populations with high rates of vaccination and BA.1/BA.2 infection.
Publisher
Cold Spring Harbor Laboratory
Reference5 articles.
1. Viana R , Moyo S , Amoako DG , et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 2022.
2. Cele S , Jackson L , Khoury DS , et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2021.
3. Liu L , Iketani S , Guo Y , et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. Nature 2021.
4. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants;N Engl J Med,2022
5. Antibody evasion properties of SARS-CoV-2 Omicron sublineages;Nature,2022